Impact of Randomized Clinical Trial Results in the National Comprehensive Cancer Network on the Use of Tamoxifen After Breast Surgery for Ductal Carcinoma in Situ

Yen, Tina W.F.; Kuerer, Henry Mark; Ottesen, Rebecca A.; Rouse, Layla; Niland, Joyce C.; Edge, Stephen B.; Theriault, Richard L.; Weeks, Jane C.

doi:10.1200/jco.2006.10.2699

Cited by 48 publications

(34 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous work reported that the use of tamoxifen reduces the 5-year rate of ipsilateral and contralateral BC in patients with DCIS; factors predicting tamoxifen use in their study were breast-conserving surgery and younger age 24. Consistent with their conclusion, our study showed that patients who took tamoxifen were less likely to elect CPM than those who did not.…”

Section: Discussionsupporting

confidence: 90%

Predictors that Influence Election of Contralateral Prophylactic Mastectomy among Women with Ductal Carcinoma in Situ who are BRCA-Negative

Elsayegh¹,

Profato²,

Barrera³

et al. 2015

J. Cancer

Self Cite

View full text Add to dashboard Cite

The authors retrospectively examined the contralateral prophylactic mastectomy (CPM) rate among 100 women with ductal carcinoma in situ who are BRCA negative. Of 100 women with ductal carcinoma in situ, 31 elected contralateral prophylactic mastectomy (CPM). Factors associated with increased likelihood of undergoing contralateral prophylactic mastectomy (CPM) among this cohort were: family history of ovarian cancer, marital status, reconstruction, mastectomy of the affected breast, and tamoxifen use.

show abstract

Section: Discussionsupporting

confidence: 90%

Predictors that Influence Election of Contralateral Prophylactic Mastectomy among Women with Ductal Carcinoma in Situ who are BRCA-Negative

Elsayegh¹,

Profato²,

Barrera³

et al. 2015

J. Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…Still, it is likely the treatment prescribed by an oncologist can be influenced by many different factors. Tamoxifen use after surgery for ductal carcinoma in situ increased after presentation of the NSABP B-24 results [16]. Rates varied substantially by institution, suggesting that physicians differ in how they weigh the benefit against the potential adverse effects.…”

Section: Discussionmentioning

confidence: 95%

Trends in the outcomes for patients with limited stage small cell lung cancer: An analysis of the Surveillance, Epidemiology, and End Results database

Lally

Geiger²,

Urbanic

et al. 2009

Lung Cancer

View full text Add to dashboard Cite

“…However, wide practice variation in recommendations for use and uptake of these therapies for DCIS suggests that communication with physicians can exert a strong influence on whether or not patients use these medications. 1,13,18,19 This study identified several patient, tumor, treatment, and physician-patient communication-related factors associated with the discussion, use, and discontinuation of adjuvant HT in a demographically and ethnically diverse sample of women.…”

Section: Discussionmentioning

confidence: 99%

“…1,11,[14][15][16][17] As a result, there is a lack of consistency in both the recommendations for and uptake of tamoxifen use in the setting of DCIS. 1,18,19 The NSABP B35 trial is currently underway to compare the effectiveness of anastrazole (an aromatase inhibitor) to that of tamoxifen in postmenopausal women with hormone receptor-positive DCIS. 11,20 Previous research into factors associated with use of adjuvant HT has focused on women with invasive breast cancer, where its use has been more consistently recommended as standard of care.…”

Section: Introductionmentioning

confidence: 99%

Adjuvant Hormonal Therapy Use Among Women with Ductal Carcinoma In Situ

Livaudais

Hwang

Karliner

et al. 2012

Journal of Women's Health

View full text Add to dashboard Cite

Objective: In the absence of consistent guidelines for the use of adjuvant hormonal therapy (HT) in treating ductal carcinoma in situ (DCIS), our purpose was to explore a variety of factors associated with discussion, use, and discontinuation of this therapy for DCIS, including patient, tumor, and treatment-related characteristics and physician-patient communication factors. Methods: We identified women from eight California Cancer Registry regions diagnosed with DCIS from 2002 through 2005, aged ‡ 18 years, of Latina or non-Latina white race/ethnicity. A total of 744 women were interviewed an average of 24 months postdiagnosis about whether they had (1) discussed with a physician, (2) used, and (3) discontinued adjuvant HT. Results: Although 83% of women discussed adjuvant HT with a physician, 47% used adjuvant HT, and 23% of users reported discontinuation by a median of 11 months. In multivariable adjusted analyses, Latina Spanish speakers were less likely than white women to discuss therapy (odds ratio [OR] 0.36, 95% confidence interval [CI] 0.18-0.69) and more likely to discontinue therapy (OR 2.67, 95% CI 1.05-6.81). Seeing an oncologist for follow-up care was associated with discussion (OR 5.10, 95% CI 3.14-8.28) and use of therapy (OR 4.20, 95% CI 2.05-8.61). Similarly, physician recommendation that treatment was necessary vs. optional was positively associated with use (OR 11.2,) and inversely associated with discontinuation (OR 0.38,. Conclusions: Physician recommendation is an important factor associated with use and discontinuation of adjuvant HT for DCIS. Differences in discussion and discontinuation of therapy according to patient characteristics, particularly ethnicity/language, suggest challenges to physician-patient communication about adjuvant HT across a language barrier.

show abstract

Impact of Randomized Clinical Trial Results in the National Comprehensive Cancer Network on the Use of Tamoxifen After Breast Surgery for Ductal Carcinoma in Situ

Cited by 48 publications

References 17 publications

Predictors that Influence Election of Contralateral Prophylactic Mastectomy among Women with Ductal Carcinoma in Situ who are BRCA-Negative

Predictors that Influence Election of Contralateral Prophylactic Mastectomy among Women with Ductal Carcinoma in Situ who are BRCA-Negative

Trends in the outcomes for patients with limited stage small cell lung cancer: An analysis of the Surveillance, Epidemiology, and End Results database

Adjuvant Hormonal Therapy Use Among Women with Ductal Carcinoma In Situ

Contact Info

Product

Resources

About